Dr. Christophe Arbet-Engels talks about some of the diabetes drugs in Boehringer Ingelheim’s pipeline including several compounds with liagliptin which BI is continuing to study and expand their knowledge of. They have looked at data in the past on African Americans and are now examining data of the drug’s efficacy in Asian populations. He explains that some drugs may work differently in different populations so they are looking at novel combinations including DPP-4/SGLT2 inhibitors possibilities as well as combining these drugs with metformin. He notes that all type 2 diabetes patients should have as full a spectrum of treatments available as possible.
Christophe Arbet-Engels, MD, PhD, MBA, is vice president, metabolic-clinical development and medical affairs, Boehringer Ingelheim Pharmaceuticals, Inc.
See more SGLT-2 Resources